Phase Ib/II trial of lenvatinib plus pembrolizumab in urothelial cancer.

被引：3
|
作者：
Vogelzang, Nicholas J.
Encarnacion, Carlos A.
Cohn, Allen Lee
DiSimone, Christopher
Rasco, Drew W.
Richards, Donald A.
Taylor, Matthew H.
Dutcus, Corina E.
Stepan, Daniel E.
Shumaker, Robert Charles
Guo, Matthew
Schmidt, Emmett V.
Mier, James Walter
机构：
[1] Comprehens Canc Ctr Nevada, Las Vegas, NV USA
[2] Texas Oncol, Waco, TX USA
[3] US Oncol, Rocky Mt Canc Ctr, Denver, CO USA
[4] Arizona Onc Assoc, Tucson, AZ USA
[5] South Texas Accelerated Res Therapeut, San Antonio, TX USA
[6] US Oncol Res, Tyler, TX USA
[7] Oregon Hlth & Sci Univ, Portland, OR 97201 USA
[8] Eisai Inc, Woodcliff Lake, NJ USA
[9] Merck & Co Inc, Kenilworth, NJ USA
[10] Dana Farber Harvard Canc Ctr, Beth Israel Deaconess Med Ctr, Boston, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 08期
关键词：
D O I：
10.1200/JCO.2019.37.8_suppl.11
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
11
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Pembrolizumab plus lenvatinib for all advanced endometrial cancer? Maybe not
    Paulino, Eduardo
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2022, 32 (04) : 579 - 579
  • [42] An open-label phase II study of lenvatinib plus pembrolizumab in patients with advanced gastric cancer (EPOC1706)
    Kawazoe, Akihito
    Fukuoka, Shota
    Nakamura, Yoshiaki
    Kuboki, Yasutoshi
    Mikamoto, Yuichi
    Shima, Hikari
    Fujishiro, Noriko
    Higuchi, Tsukiko
    Wakabayashi, Masashi
    Nomura, Shogo
    Sato, Akihiro
    Shitara, Kohei
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [43] A phase II single-arm study of pembrolizumab plus lenvatinib in previously treated classic Kaposi sarcoma (CKS): The PULSAR trial
    Indini, A.
    Tourlaki, A.
    Barbin, F.
    Brambilla, L.
    Gambini, D.
    Berti, E.
    Grossi, F.
    ANNALS OF ONCOLOGY, 2021, 32 : S1128 - S1128
  • [44] Phase Ib/II Study of Cetuximab plus Pembrolizumab in Patients with Advanced RAS Wild-Type Colorectal Cancer
    Fountzilas, Christos
    Bajor, David L.
    Mukherjee, Sarbajit
    Saltzman, Joel
    Witkiewicz, Agnieszka K.
    Maguire, Orla
    Minderman, Hans
    Nambiar, Ram
    Rosenheck, Hanna R.
    Knudsen, Erik S.
    Muhitch, Jason B.
    Abrams, Scott, I
    Wang, Chong
    Hutson, Alan D.
    Attwood, Kristopher
    Hicks, Karen A.
    Jurcevic, Jennifer A.
    Kalinski, Pawel
    Iyer, Renuka
    Boland, Patrick M.
    CLINICAL CANCER RESEARCH, 2021, 27 (24) : 6726 - 6736
  • [45] A phase 1b/2 trial of lenvatinib plus pembrolizumab in patients with renal cell carcinoma
    Lee, C-H.
    Makker, V.
    Rasco, D.
    Taylor, M.
    Dutcus, C.
    Shumaker, R.
    Schmidt, E. V.
    Stepan, D.
    Li, D.
    Motzer, R. J.
    ANNALS OF ONCOLOGY, 2017, 28
  • [46] A PHASE IB TRIAL OF ZIV-AFLIBERCEPT PLUS PEMBROLIZUMAB IN PATIENTS WITH ADVANCED SOLID TUMORS
    Tyan, Kevin
    Rahma, Osama
    Giobbie-Hurder, Anita
    Brohl, Andrew
    Bedard, Philippe
    Renouf, Daniel
    Sharon, Elad
    Streicher, Howard
    Hathaway, Emma
    Cunningham, Rachel
    Manos, Michael
    Severgnini, Mariano
    Rodig, Scott
    Hodi, F. Stephen
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A402 - A404
  • [47] Phase 1 trial of the anti-LAG3 antibody favezelimab plus pembrolizumab in advanced gastric cancer.
    Rha, Sun Young
    Miller, Wilson H.
    de Miguel, Maria Jose
    Im, Seock-Ah
    Lugowska, Iwona
    Wermke, Martin
    Kotani, Daisuke
    Bauer, Todd Michael
    Takashima, Atsuo
    Palcza, John
    Chaney, Marya F.
    Dobrenkov, Konstantin
    Garralda, Elena
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 394 - 394
  • [48] Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002) a randomised, double-blind, phase 3 trial
    Llovet, Josep M.
    Kudo, Masatoshi
    Merle, Philippe
    Meyer, Tim
    Qin, Shukui
    Ikeda, Masafumi
    Xu, Ruocai
    Edeline, Julien
    Ryoo, Baek-Yeol
    Ren, Zhenggang
    Masi, Gianluca
    Kwiatkowski, Mariusz
    Lim, Ho Yeong
    Kim, Jee Hyun
    Breder, Valeriy
    Kumada, Hiromitsu
    Cheng, Ann-Lii
    Galle, Peter R.
    Kaneko, Shuichi
    Wang, Anran
    Mody, Kalgi
    Dutcus, Corina
    Dubrovsky, Leonid
    Siegel, Abby B.
    Finn, Richard S.
    LANCET ONCOLOGY, 2023, 24 (12): : 1399 - 1410
  • [49] Phase II trial of irinotecan plus bevacizumab for heavily pretreated recurrent ovarian cancer.
    Jain, Salvia Sanjay
    Makeyev, Yan G.
    Muggia, Franco
    Speyer, James L.
    Curtin, John Patrick
    Blank, Stephanie V.
    Boyd, Leslie R.
    Pothuri, Bhavana
    Fishman, David
    Li, Xiaochun
    Goldberg, Judith D.
    Tiersten, Amy
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [50] A phase ib trial to evaluate the safety and efficacy of quinacrine plus capecitabine in patients with refractory metastatic colorectal cancer.
    Winer, Arthur
    Vijayvergia, Namrata
    Cohen, Steven J.
    Denlinger, Crystal S.
    Astsaturov, Igor A.
    Dotan, Efrat
    Gallant, Jean-Nicolas
    Wang, Edward W.
    Kunkel, Miriam
    Lim, Bora
    Harvey, Harold A.
    Sivik, Jeffrey Michael
    Zhou, Lanlan
    Korzekwa, Kenneth
    Ruth, Karen
    Ross, Eric A.
    El-Deiry, Wafik S.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345